Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Blue Earth Therapeutics Ltd
University Health Network, Toronto
Wake Forest University Health Sciences
National Institutes of Health Clinical Center (CC)
Pathos AI, Inc.
National Institutes of Health Clinical Center (CC)
K36 Therapeutics, Inc.
M.D. Anderson Cancer Center
Varian, a Siemens Healthineers Company
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
University of California, Irvine
Washington University School of Medicine
Spanish Oncology Genito-Urinary Group
DL Analytics
Centre Hospitalier Universitaire de Nīmes
National Institutes of Health Clinical Center (CC)
Wake Forest University Health Sciences
RenJi Hospital
The Netherlands Cancer Institute
Jinling Hospital, China
Queen Mary University of London
Johns Hopkins University
British Columbia Cancer Agency
The Netherlands Cancer Institute
RefleXion Medical
Universitaire Ziekenhuizen KU Leuven
Ottawa Hospital Research Institute
Marengo Therapeutics, Inc.
University of California, Irvine
Endocyte
Stanford University
UroGen Pharma Ltd.
Algemeen Ziekenhuis Maria Middelares
University Health Network, Toronto
Regina Elena Cancer Institute
University Health Network, Toronto
VA Greater Los Angeles Healthcare System
Mabwell (Shanghai) Bioscience Co., Ltd.
University of Toronto
Sheba Medical Center